News

Targeted Oncology12m
FDA Accepts NDA for Vepdegestrant in ER+/HER2- Metastatic Breast Cancer
The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...
GSK's antibiotic gets FDA priority review for oral treatment of gonorrhoea
(Reuters) -British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for ...
Oragenics Q2 2025 Shareholder Update
Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OG ...
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer
Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.